康弘药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：阿尔茨海默、创新 药、生物医药、眼科概念、合成生物等。 截至10月10日，康弘药业股东户数2.40万，较上期增加0.20%；人均流通股28565股，较上期减少 0.20%。2025年1月-6月，康弘药业实现营业收入24.54亿元，同比增长6.95%；归母净利润7.30亿元，同 比增长5.41%。 分红方面，康弘药业A股上市后累计派现20.38亿元。近三年，累计派现10.40亿元。 10月24日，康弘药业盘中下跌2.03%，截至13:24，报32.38元/股，成交1.32亿元，换手率0.59%，总市值 298.32亿元。 资金流向方面，主力资金净流入229.77万元，特大单买入100.57万元，占比0.76%，卖出129.84万元，占 比0.99%；大单买入1202.02万元，占比9.13%，卖出942.98万元，占比7.16%。 康弘药业今年以来股价涨70.42%，近5个交易日跌7.11%，近20日跌17.82%，近60日跌20.81%。 今年以来康弘药业已经1次登上龙虎榜，最近一次登上龙虎榜为7月21日。 资料显示，成都康弘药业集团 ...

10月23日，康弘药业盘中下跌2.01%，截至10:11，报32.60元/股，成交4979.75万元，换手率0.22%，总 市值300.35亿元。 截至10月10日，康弘药业股东户数2.40万，较上期增加0.20%；人均流通股28565股，较上期减少 0.20%。2025年1月-6月，康弘药业实现营业收入24.54亿元，同比增长6.95%；归母净利润7.30亿元，同 比增长5.41%。 今年以来康弘药业已经1次登上龙虎榜，最近一次登上龙虎榜为7月21日。 资料显示，成都康弘药业集团股份有限公司位于四川省成都市金牛区蜀西路108号，成立日期1996年10 月3日，上市日期2015年6月26日，公司主营业务涉及化学药、中成药及生物制品的研发、生产与销售。 主营业务收入构成为：生物药54.83%，中成药32.49%，化学药12.50%，其他0.15%，其他(补 充)0.03%。 康弘药业所属申万行业为：医药生物-生物制品-其他生物制品。所属概念板块包括：创新药、阿尔茨海 默、生物医药、眼科概念、中药等。 分红方面，康弘药业A股上市后累计派现20.38亿元。近三年，累计派现10.40亿元。 资金流向方面，主力资金净流 ...

Company Overview - Rongchang Biopharmaceuticals is an innovative biopharmaceutical company focused on antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies, and bispecific antibodies [2] - The company aims to discover, develop, and commercialize innovative and distinctive first-in-class and best-in-class biopharmaceuticals to address unmet clinical needs in autoimmune diseases, oncology, and ophthalmology [2] - Main business revenue composition includes 99.46% from product sales, 0.38% from material sales, and 0.16% from leasing services [2] Financial Performance - As of June 30, 2025, Rongchang Biopharmaceuticals reported a revenue of 1.098 billion yuan, a year-on-year increase of 48.02% [3] - The net profit attributable to shareholders was -450 million yuan, reflecting a year-on-year growth of 42.40% [3] Shareholder and Market Activity - As of June 30, 2025, the number of shareholders increased to 12,900, up 90.69% from the previous period, while the average circulating shares per person decreased by 47.56% to 12,595 shares [3] - The stock price experienced a significant increase of 209.47% year-to-date, but has seen a decline of 6.07% in the last five trading days and 10.22% in the last 20 days [1] - Major shareholders include Hong Kong Central Clearing Limited as the second-largest shareholder with 9.3526 million shares, and several new institutional investors have entered the top ten shareholders list [4]

资料显示，贝达药业股份有限公司位于浙江省杭州市临平区经济技术开发区兴中路355号,香港铜锣湾希 慎道33号利园1期19楼1919室，成立日期2003年1月7日，上市日期2016年11月7日，公司主营业务涉及药 品的研发、生产和销售。主营业务收入构成为：药品销售99.10%，其他(补充)0.90%。 贝达药业所属申万行业为：医药生物-化学制药-化学制剂。所属概念板块包括：眼科概念、抗癌治癌、 抗癌药物、创新药、生物医药等。 10月23日，贝达药业盘中下跌2.03%，截至09:47，报57.08元/股，成交3774.79万元，换手率0.16%，总 市值240.15亿元。 资金流向方面，主力资金净流出442.88万元，特大单买入0.00元，占比0.00%，卖出218.89万元，占比 5.80%；大单买入502.80万元，占比13.32%，卖出726.80万元，占比19.25%。 贝达药业今年以来股价涨6.23%，近5个交易日跌2.94%，近20日跌16.83%，近60日跌8.99%。 分红方面，贝达药业A股上市后累计派现6.69亿元。近三年，累计派现1.84亿元。 机构持仓方面，截止2025年6月30日，贝达药业十 ...

Core Viewpoint - Kanghong Pharmaceutical's stock has experienced a significant increase of 74.32% year-to-date, but has recently seen declines in the short term, with a drop of 5.53% over the last five trading days and 22.62% over the last 60 days [1] Financial Performance - For the first half of 2025, Kanghong Pharmaceutical reported a revenue of 2.454 billion yuan, representing a year-on-year growth of 6.95%, and a net profit attributable to shareholders of 730 million yuan, which is a 5.41% increase compared to the previous year [2] Shareholder Information - As of October 10, 2025, the number of shareholders for Kanghong Pharmaceutical increased to 24,000, with an average of 28,565 circulating shares per person, a slight decrease of 0.20% [2] - The company has distributed a total of 2.038 billion yuan in dividends since its A-share listing, with 1.04 billion yuan distributed over the last three years [3] Stock Market Activity - On October 22, Kanghong Pharmaceutical's stock price was 33.12 yuan per share, with a total market capitalization of 30.514 billion yuan. The stock saw a net outflow of 5.403 million yuan in principal funds [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on July 21 [1] Business Composition - Kanghong Pharmaceutical's main business revenue composition includes: biopharmaceuticals at 54.83%, traditional Chinese medicine at 32.49%, chemical drugs at 12.50%, and other categories at 0.18% [1] - The company operates in the pharmaceutical and biotechnology sector, focusing on innovative drugs, biomedicine, Alzheimer's treatment, traditional Chinese medicine, and ophthalmology [1]

机构持仓方面，截止2025年6月30日，荣昌生物十大流通股东中，香港中央结算有限公司位居第二大流 通股东，持股935.26万股，为新进股东。万家优选（161903）位居第五大流通股东，持股592.45万股， 为新进股东。工银前沿医疗股票A（001717）位居第六大流通股东，持股400.00万股，为新进股东。鹏 华医药科技股票A（001230）位居第七大流通股东，持股388.17万股，相比上期减少79.51万股。汇添富 创新医药混合A（006113）位居第八大流通股东，持股314.18万股，为新进股东。招商国证生物医药指 数A（161726）位居第九大流通股东，持股281.24万股，相比上期减少21.74万股。中银创新医疗混合A （007718）位居第十大流通股东，持股264.64万股，相比上期减少185.60万股。汇添富医疗服务灵活配 置混合A（001417）退出十大流通股东之列。 责任编辑：小浪快报 资料显示，荣昌生物制药(烟台)股份有限公司位于中国(山东)自由贸易试验区烟台片区烟台开发区北京 中路58号，成立日期2008年7月4日，上市日期2022年3月31日，公司主营业务涉及公司是一家具有全球 化视野的 ...

10月21日，博士眼镜盘中上涨2.00%，截至10:24，报30.09元/股，成交6461.55万元，换手率1.40%，总 市值68.56亿元。 资金流向方面，主力资金净流入389.85万元，大单买入1247.08万元，占比19.30%，卖出857.22万元，占 比13.27%。 截至6月30日，博士眼镜股东户数5.38万，较上期增加9.25%；人均流通股2892股，较上期增加19.81%。 2025年1月-6月，博士眼镜实现营业收入6.86亿元，同比增长14.22%；归母净利润5603.34万元，同比增 长6.97%。 分红方面，博士眼镜A股上市后累计派现4.64亿元。近三年，累计派现2.04亿元。 机构持仓方面，截止2025年6月30日，博士眼镜十大流通股东中，广发创新升级混合（002939）位居第 四大流通股东，持股192.90万股，为新进股东。民生加银持续成长混合A（007731）位居第五大流通股 东，持股150.00万股，为新进股东。广发价值核心混合A（010377）位居第七大流通股东，持股74.34万 股，为新进股东。鹏华创新未来混合(LOF)（501205）、中信建投医改A（002408）退出十 ...

Core Viewpoint - Kanghong Pharmaceutical's stock has experienced a significant increase of 79.79% year-to-date, but has recently seen a decline in the short term, with a drop of 2.62% over the last five trading days and 13.01% over the last twenty days [1] Financial Performance - For the first half of 2025, Kanghong Pharmaceutical reported a revenue of 2.454 billion yuan, representing a year-on-year growth of 6.95%, and a net profit attributable to shareholders of 730 million yuan, which is a 5.41% increase compared to the previous year [2] Shareholder Information - As of October 10, 2025, the number of shareholders for Kanghong Pharmaceutical increased to 24,000, with an average of 28,565 circulating shares per person, a slight decrease of 0.20% [2] - The company has distributed a total of 2.038 billion yuan in dividends since its A-share listing, with 1.04 billion yuan distributed over the last three years [3] Stock Performance and Trading Activity - On October 20, Kanghong Pharmaceutical's stock price was 34.16 yuan per share, with a market capitalization of 31.472 billion yuan. The stock saw a net outflow of 3.3859 million yuan in principal funds, with large orders accounting for 12.28% of purchases and 15.13% of sales [1] - The company has appeared on the "Dragon and Tiger List" once this year, with the most recent occurrence on July 21 [1] Business Segmentation - Kanghong Pharmaceutical's main business revenue composition includes: biopharmaceuticals at 54.83%, traditional Chinese medicine at 32.49%, chemical drugs at 12.50%, and other segments at 0.18% [1] - The company operates within the pharmaceutical and biotechnology industry, focusing on innovative drugs, biomedicine, traditional Chinese medicine, Alzheimer's disease, and ophthalmology concepts [1]

Core Viewpoint - Yuyue Medical's stock price has shown fluctuations, with a recent decline of 2.05% on October 17, 2023, reflecting a total market capitalization of 37.38 billion yuan and a year-to-date increase of 3.90% [1] Financial Performance - For the first half of 2025, Yuyue Medical reported a revenue of 4.659 billion yuan, representing a year-on-year growth of 8.16%, and a net profit attributable to shareholders of 1.203 billion yuan, which is a 7.37% increase compared to the previous year [2] Shareholder Information - As of September 30, 2023, the number of shareholders for Yuyue Medical stood at 50,000, with an average of 18,803 circulating shares per person, indicating no change from the previous period [2] - The company has distributed a total of 4.415 billion yuan in dividends since its A-share listing, with 2.402 billion yuan distributed over the last three years [3] Institutional Holdings - As of June 30, 2025, the top circulating shareholders include Huabao Zhongzheng Medical ETF, holding 20.005 million shares, an increase of 347,900 shares from the previous period, while Hong Kong Central Clearing Limited reduced its holdings by 6.963 million shares [3]

Group 1 - The core viewpoint of the news is that 恒瑞医药 (Hengrui Medicine) has shown significant stock performance with a year-to-date increase of 43.61%, despite recent declines in the last five and twenty trading days [1][3] - As of October 15, the stock price reached 65.63 yuan per share, with a market capitalization of 435.99 billion yuan and a trading volume of 19.98 billion yuan [1] - The company has experienced a net inflow of main funds amounting to 33.03 million yuan, with significant buying and selling activities from large orders [1] Group 2 - 恒瑞医药 is primarily engaged in the research, production, and sales of pharmaceuticals, focusing on oncology and related fields such as kinase inhibitors and antibody-drug conjugates [2] - The company's revenue composition includes 86.88% from product sales, 12.63% from licensing income, and 0.49% from other sources [2] - As of June 30, the company reported a revenue of 15.76 billion yuan for the first half of 2025, reflecting a year-on-year growth of 15.88%, and a net profit of 4.45 billion yuan, up 29.67% [3] Group 3 - Since its A-share listing, 恒瑞医药 has distributed a total of 9.30 billion yuan in dividends, with 3.57 billion yuan distributed in the last three years [4] - As of June 30, 2025, the number of shareholders decreased to 364,700, while the average circulating shares per person increased by 12.70% [3][4] - Major institutional shareholders include Hong Kong Central Clearing Limited and various ETFs, with notable increases in their holdings [4]